You just read:

Seal Rock Therapeutics Advancing Differentiated ASK1 Inhibitor Lead Candidate SRT-015 in Nonalcoholic Steatohepatitis (NASH)

News provided by

Seal Rock Therapeutics, Inc.

Nov 09, 2018, 08:00 ET